Three-year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial.

Warren, R B; Lebwohl, M; Sofen, H; Piguet, V; Augustin, M; Brock, F; Fierens, F; Blauvelt, A

Warren, R B; Lebwohl, M; Sofen, H; Piguet, V; Augustin, M; Brock, F; Fierens, F; Blauvelt, A.

Afiliación

Warren RB; Dermatology Centre, Salford Royal NHS Foundation Trust, Manchester NIHR Biomedical Research Centre, The University of Manchester, Manchester, UK.
Lebwohl M; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sofen H; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Piguet V; Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Augustin M; Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, ON, Canada.
Brock F; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
C Arendt; UCB Pharma, Slough, UK.
Fierens F; UCB Pharma, Brussels, Belgium.
Blauvelt A; UCB Pharma, Brussels, Belgium.

J Eur Acad Dermatol Venereol ; 35(12): 2398-2408, 2021 Dec.

Article en En | MEDLINE | ID: mdl-34192387

Asunto(s)

Psoriasis; Adulto; Certolizumab Pegol/efectos adversos; Método Doble Ciego; Etanercept; Humanos; Psoriasis/tratamiento farmacológico; Resultado del Tratamiento

Palabras clave

certolizumab pegol; clinical trial; long term; plaque psoriasis

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: J Eur Acad Dermatol Venereol Asunto de la revista: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Año: 2021 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google